Research Article
Molecular Epidemiology of Invasive Listeriosis due to Listeria monocytogenes in a Spanish Hospital over a Nine-Year Study Period, 2006–2014
Table 2
Antimicrobial susceptibility of 17 L. monocytogenes isolates in the E-test.
| | Antibiotic | MIC (mg/L) | Susceptibility breakpoint (mg/L) | % susceptibility | | Range | 50% | 90% |
| | Benzylpenicillin | 0.064–1 | 0.25 | 0.75 | ≤1 | 100 | | Ampicillin | 0.064–1 | 0.25 | 0.75 | ≤1 | 100 | | Imipenem | 0.125–0.19 | 0.19 | 0.19 | — | — | | Meropenem | 0.19–0.75 | 0.38 | 0.38 | ≤0.25 | 58.8 | | Erythromycin | 0.125–0.38 | 0.25 | 0.38 | ≤1 | 100 | | Clindamycin | 0.25–8 | 2 | 4 | — | — | | Gentamicin | 0.094–1 | 0.25 | 0.5 | — | — | | Vancomycin | 0.75–1.5 | 1.5 | 1.5 | — | — | | Daptomycin | 0.75–1.5 | 1 | 1.5 | — | — | | Linezolid | 1-2 | 2 | 2 | — | — | | Ciprofloxacin | 0.5–2 | 1 | 1.5 | — | — | | Moxifloxacin | 0.19–0.5 | 0.38 | 0.5 | — | — | | Tetracycline | 0.094–1.5 | 1 | 1.5 | — | — | | Tigecycline | 0.094–1.5 | 0.125 | 0.25 | — | — | | Rifampin | 0.023–0.19 | 0.094 | 0.125 | — | — | | Cotrimoxazole | 0.008–0.023 | 0.012 | 0.019 | ≤0.06 | 100 |
|
|
According to EUCAST antimicrobial susceptibility breakpoints for L. monocytogenes.
|
